Resultados da pesquisa - ((safety alert) OR (safety after)) armed phase 1

Pesquisas alternativas:
safety alert » safety alerts (Expandir a Pesquisa), safety belt (Expandir a Pesquisa), safety audit (Expandir a Pesquisa)
armed phase » formed phase (Expandir a Pesquisa), aided phase (Expandir a Pesquisa), red phase (Expandir a Pesquisa)
phase 1 » phase _ (Expandir a Pesquisa), phase 2 (Expandir a Pesquisa)

201

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Por Munster, Pamela, Krop, Ian E., LoRusso, Patricia, Ma, Cynthia, Siegel, Barry A., Shields, Anthony F., Molnár, István, Wickham, Thomas J., Reynolds, Joseph, Campbell, Karen, Hendriks, Bart S., Adiwijaya, Bambang S., Geretti, Elena, Moyo, Victor, Miller, Kathy D.
Publicado no Br J Cancer (2018)

“...BACKGROUND: This phase 1 dose-escalation trial studied MM-302, a novel HER2-targeted PEGylated...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

202

A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer

A phase I/II trial of irinotecan–cisplatin combined with an anti-late-diarrhoeal programme...

Por Takeda, Y, Tsuduki, E, Izumi, S, Hojo, M, Kamimura, M, Naka, G, Kobayashi, K, Kudo, K
Publicado em 2005

“...We conducted a phase I/II study in patients with advanced non-small-cell lung cancer (NSCLC...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

203

2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age

2490. A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage Finding Study to Evaluate...

Por Otten, Gillis, Matassa, Vince, Ciarlet, Max, Leav, Brett
Publicado no Open Forum Infect Dis (2018)

“... study with seven treatment arms to assess the safety and immunogenicity of the current formulation...”
Obter o texto integral
Obter o texto integral

Artigo

204

Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy and quality of life Of a human recombinant alkaline Phosphatase in patients with sepsis-associated Acute Kidney Injury (STOP-AKI)

Study protocol for a multicentre randomised controlled trial: Safety, Tolerability, efficacy...

Por Peters, Esther, Mehta, Ravindra L, Murray, Patrick T, Hummel, Jürgen, Joannidis, Michael, Kellum, John A, Arend, Jacques, Pickkers, Peter
Publicado no BMJ Open (2016)

“...-blind, placebo-controlled, 4-arm, proof-of-concept, dose-finding adaptive phase IIa/IIb study, conducted...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

205

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

Por Molina, Ana M., Hutson, Thomas E., Nosov, Dmitry, Tomczak, Piotr, Lipatov, Oleg, Sternberg, Cora N., Motzer, Robert, Eisen, Tim
Publicado no Eur J Cancer (2018)

“... with advanced renal cell carcinoma (RCC). METHODS: Patients enrolled in this single-arm, phase 2 crossover study...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

206

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA

Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing...

Por V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva
Publicado em 2020-09-01

“... [27,4%; 48,1%]). Spinal pain subsided and laboratory inflammation markers decreased within one week...”
Obter o texto integral

Artigo

207

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety...

Por Povsic, Thomas J., Vavalle, John P., Aberle, Laura H., Kasprzak, Jaroslaw D., Cohen, Mauricio G., Mehran, Roxana, Bode, Christoph, Buller, Christopher E., Montalescot, Gilles, Cornel, Jan H., Rynkiewicz, Andrzej, Ring, Michael E., Zeymer, Uwe, Natarajan, Madhu, Delarche, Nicolas, Zelenkofske, Steven L., Becker, Richard C., Alexander, John H.
Publicado em 2013

“... revascularization, or recurrent ischaemia. Enrolment in the 25% reversal arm was suspended after 41 patients...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

208

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety...

Por de Jong, Wesley, Aerts, Joeri, Allard, Sabine, Brander, Christian, Buyze, Jozefien, Florence, Eric, van Gorp, Eric, Vanham, Guido, Leal, Lorna, Mothe, Beatriz, Thielemans, Kris, Plana, Montse, Garcia, Félipe, Gruters, Rob
Publicado no Trials (2019)

“..., multicenter study in chronically HIV-1 infected patients under stable cART. One of the three study arms...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

209

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy

iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety...

Por Wesley de Jong, Joeri Aerts, Sabine Allard, Christian Brander, Jozefien Buyze, Eric Florence, Eric van Gorp, Guido Vanham, Lorna Leal, Beatriz Mothe, Kris Thielemans, Montse Plana, Félipe Garcia, Rob Gruters, on behalf of the iHIVARNA consortium
Publicado em 2019-06-01

Assuntos: “...HIV-1...”
Obter o texto integral

Artigo

210

ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING WITH A NINE-EMITTER IMPLANTABLE ULTRASOUND DEVICE IN RECURRENT GLIOBLASTOMA PATIENTS PRIOR TO CARBOPLATIN

ACTR-57. A PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLOOD-BRAIN BARRIER (BBB) OPENING...

Por Idbaih, Ahmed, Ducray, François, DeGroot, John, Stupp, Roger, Guyotat, Jacques, Lesniak, Maciej S, Sonabend, Adam, Weinberg, Jeffrey, Desseaux, Carole, Canney, Michael, Schmitt, Charlotte, Carpentier, Alexandre
Publicado no Neuro Oncol (2019)

“... infusion at AUC5. This ongoing pilot phase 1/2 study (NCT03744026) aims to evaluate the safety and efficacy...”
Obter o texto integral
Obter o texto integral

Artigo

211

Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)

Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II)

Por Qingsong Ye, Hua Wang, Xia Xia, Chenliang Zhou, Zhiming Liu, Zun-en Xia, Zhan Zhang, Yang Zhao, Jun Yehenala, Si Wang, Gangqiao Zhou, Ke Hu, Bin Wu, Chu-Tse Wu, Songling Wang, Yan He
Publicado em 2020-06-01

“... centre, two arm ratio 1:1, triple blinded, randomized, placebo-controlled, parallel group, clinical trial...”
Obter o texto integral

Artigo

212

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia

Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated...

Por MOUNTZIOS, GIANNIS, ARAVANTINOS, GERASIMOS, ALEXOPOULOU, ZOI, TIMOTHEADOU, ELENI, MATSIAKOU, FOTINI, CHRISTODOULOU, CHRISTOS, LASCHOS, KONSTANTINOS, GALANI, ELENI, KOUTRAS, ANGELOS, BAFALOUKOS, DIMITRIOS, LINARDOU, HELENA, PECTASIDES, DIMITRIOS, VARTHALITIS, IOANNIS, PAPAKOSTAS, PAVLOS, KALOFONOS, HARALAMBOS P., FOUNTZILAS, GEORGE
Publicado no Mol Clin Oncol (2016)

“..., randomized phase III trial of prophylactic vs. hemoglobin (Hb)-based (threshold: 11 mg/dl) ESA administration...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

213

Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02)

Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02)

Por Yoshida, Yoichiro, Aisu, Naoya, Kojima, Daibo, Mera, Toshiyuki, Kiyomi, Fumiaki, Yamashita, Yuichi, Hasegawa, Suguru
Publicado no Ann Gastroenterol Surg (2017)

“... after resecting primary colorectal cancer with distant metastases. We aimed to determine the safety...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

214

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer: A Phase 2 Trial

Por Bauml, Joshua M., Mick, Rosemarie, Ciunci, Christine, Aggarwal, Charu, Davis, Christiana, Evans, Tracey, Deshpande, Charuhas, Miller, Linda, Patel, Pooja, Alley, Evan, Knepley, Christina, Mutale, Faith, Cohen, Roger B., Langer, Corey J.
Publicado no JAMA Oncol (2019)

“...: This single-arm phase 2 trial of pembrolizumab therapy was performed from February 1, 2015, through September...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

215

Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally advanced pancreatic cancer (SILAPANC) trial: study design and rationale of a phase II clinical trial

Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously...

Por Zhu, Xiaofei, Ju, Xiaoping, Cao, Fei, Fang, Fang, Qing, Shuiwang, Shen, Yuxin, Jia, Zhen, Cao, Yangsen, Zhang, Huojun
Publicado no BMJ Open (2016)

“... prospective, single-centre, one armed ongoing study. 190 eligible patients are required to initially receive...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

216

Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure

Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure

Por Green, Angela K., Corty, Robert W., Wood, William A., Meeneghan, Mathew, Reeder-Hayes, Katherine E., Basch, Ethan, Milowsky, Matthew I., Dusetzina, Stacie B.
Publicado no Oncologist (2015)

“... with mitoxantrone and prednisone. PATIENTS AND METHODS. Control arm data from two phase III randomized control...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

217

ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

ACTR-15. SAFETY AND PRELIMINARY ACTIVITY OF PT2385, A FIRST-IN-CLASS HIF2-ALPHA INHIBITOR, PLANNED INTERIM ANALYSIS OF AN OPEN LABEL, SINGLE-ARM PHASE II STUDY IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Por Strowd, Roy, Ellingson, Benjamin, Wen, Patrick, Ahluwalia, Manmeet, Piotrowski, Anna, Desai, Arati, Clarke, Jennifer, Lieberman, Frank, Desideri, Serena, Nabors, L Burt, Grossman, Stuart
Publicado no Neuro Oncol (2018)

“...-agent activity against glioblastoma (GBM). METHODS: A single-arm open-label phase II study of adults...”
Obter o texto integral
Obter o texto integral

Artigo

218

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus...

Por Nakayama, Goro, Ishigure, Kiyoshi, Yokoyama, Hiroyuki, Uehara, Keisuke, Kojima, Hiroshi, Ishiyama, Akiharu, Hayashi, Naomi, Takano, Nao, Hattori, Norifumi, Kobayashi, Daisuke, Tanaka, Chie, Hayashi, Masamichi, Kanda, Mitsuro, Yamada, Suguru, Sugimoto, Hiroyuki, Koike, Masahiko, Fujiwara, Michitaka, Fujii, Tsutomu, Murotani, Kenta, Ando, Yuichi, Kodera, Yasuhiro
Publicado no BMC Cancer (2017)

“...BACKGROUND: The aim of this study was to evaluate the efficacy and safety of CapeOX plus...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

219

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Por Hutson, Thomas E., Escudier, Bernard, Esteban, Emilio, Bjarnason, Georg A., Lim, Ho Yeong, Pittman, Kenneth B., Senico, Peggy, Niethammer, Andreas, Lu, Dongrui Ray, Hariharan, Subramanian, Motzer, Robert J.
Publicado no J Clin Oncol (2014)

“... in the temsirolimus and sorafenib arms was 12.3 and 16.6 months, respectively. Safety profiles of both agents were...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

220

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

Por Rosenberg, Jonathan E., O’Donnell, Peter H., Balar, Arjun V., McGregor, Bradley A., Heath, Elisabeth I., Yu, Evan Y., Galsky, Matthew D., Hahn, Noah M., Gartner, Elaina M., Pinelli, Juan M., Liang, Shang-Ying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Publicado no J Clin Oncol (2019)

“... global, phase II, single-arm study of enfortumab vedotin 1.25 mg/kg (intravenously on days 1, 8, and 15...”
Obter o texto integral
Obter o texto integral
Obter o texto integral

Artigo

[1]
Anterior
6
7
8
9
10
11
12
13
14
15
16
Seguinte
[39]